BioLineRx Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
BLRX
IL0011015182
Biotechnology & Medical Research
Sales 2024 * | 14.36M 53.55M | Sales 2025 * | 27.77M 104M | Capitalization | 52.59M 196M |
---|---|---|---|---|---|
Net income 2024 * | -47M -175M | Net income 2025 * | -36M -134M | EV / Sales 2024 * | 3.66 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.89 x |
P/E ratio 2024 * |
-2.22
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on BioLineRx Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 09-05-23 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 08-12-31 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 14-02-23 |
Avraham Molcho
BRD | Director/Board Member | 66 | 09-12-31 |
Aharon Schwartz
CHM | Chairman | 80 | 03-12-31 |
1st Jan change | Capi. | |
---|---|---|
+2.99% | 108B | |
+10.35% | 105B | |
+1.57% | 23.46B | |
-12.61% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-7.42% | 17.19B | |
+6.18% | 13.99B | |
+38.02% | 12.53B |